European Society of Human Reproduction and Embryology

Fertilix Proven Effective in Blocking Damage From Low-Dose Exposure to Chemicals Commonly Found in Plastic Consumer Products

Retrieved on: 
Thursday, May 18, 2023
Male, DNA, Biotechnology, ESHRE, Pollution, Microplastics, Fertility clinic, Dibutyl phthalate, Risk, Fertility, Human Reproduction (journal), AF, European Society of Human Reproduction and Embryology, Health, Reproductive endocrinology and infertility, Female, Dietary supplement, Antioxidant, Embryology

The study, led by Professor Joel Drevet, examined two common chemicals widely used in the plastic industry: dibutyl phthalate and bisphenol AF.

Key Points: 
  • The study, led by Professor Joel Drevet, examined two common chemicals widely used in the plastic industry: dibutyl phthalate and bisphenol AF.
  • These chemicals have long been linked to lowering male fertility, but the novelty of this study was in evaluating doses that were previously considered safe or inconsequential for consumers.
  • Interestingly, the study also showed that co-administration with micronutrient supplement Fertilix(R) significantly blocked the damaging effects of these chemicals on sperm DNA.
  • This study is now available with open-access in Antioxidants, a premier journal in antioxidant research, and can be downloaded here.

Lo.Li. Pharma International and its International Partners Achieve a New World Record to Raise Awareness About Innovative Options for Managing PCOS and Infertility

Retrieved on: 
Wednesday, June 28, 2023
Inositol, ESHRE, Education, Society for Human Resource Management, Infertility, European Society of Human Reproduction and Embryology, Polycystic ovary syndrome, Patient, PCOS, Diagnosis, Pharmaceutical industry, Medical device, Embryology

The record-breaking event aimed to raise awareness about non-pharmacological options for managing polycystic ovary syndrome (PCOS) and infertility.

Key Points: 
  • The record-breaking event aimed to raise awareness about non-pharmacological options for managing polycystic ovary syndrome (PCOS) and infertility.
  • Inositol, a naturally occurring compound that plays a vital role in cellular signaling, has shown promise in managing PCOS and infertility.
  • This monumental achievement marks a significant step toward raising awareness about the importance of non-pharmacological options for managing PCOS and infertility.
  • By fostering awareness, collaboration, and innovative solutions, the company aims to make a lasting impact on women's reproductive health and well-being.

Lo.Li. Pharma International and its International Partners Achieve a New World Record to Raise Awareness About Innovative Options for Managing PCOS and Infertility

Retrieved on: 
Wednesday, June 28, 2023
Inositol, ESHRE, Education, Society for Human Resource Management, Infertility, European Society of Human Reproduction and Embryology, Polycystic ovary syndrome, Patient, PCOS, Diagnosis, Pharmaceutical industry, Medical device, Embryology

The record-breaking event aimed to raise awareness about non-pharmacological options for managing polycystic ovary syndrome (PCOS) and infertility.

Key Points: 
  • The record-breaking event aimed to raise awareness about non-pharmacological options for managing polycystic ovary syndrome (PCOS) and infertility.
  • Inositol, a naturally occurring compound that plays a vital role in cellular signaling, has shown promise in managing PCOS and infertility.
  • This monumental achievement marks a significant step toward raising awareness about the importance of non-pharmacological options for managing PCOS and infertility.
  • By fostering awareness, collaboration, and innovative solutions, the company aims to make a lasting impact on women's reproductive health and well-being.

OmicsEdge Unveils Groundbreaking Genotype Imputation Method at European Society of Human Genetics Meeting

Retrieved on: 
Tuesday, June 27, 2023
Drug discovery, Whole genome sequencing, Human genetics, Extremities, Disease, European Society of Human Genetics, Medicine, Benchmarking, Health, European Society of Human Reproduction and Embryology, Genetics, Vaccine

GLASGOW, United Kingdom, June 27, 2023 /PRNewswire/ -- OmicsEdge, a vanguard in genetic technology, is delighted to announce the presentation of its new genotype imputation method at the European Society of Human Genetics (ESHG) meeting in Glasgow.

Key Points: 
  • GLASGOW, United Kingdom, June 27, 2023 /PRNewswire/ -- OmicsEdge, a vanguard in genetic technology, is delighted to announce the presentation of its new genotype imputation method at the European Society of Human Genetics (ESHG) meeting in Glasgow.
  • Genotype imputation is a statistical technique that predicts unknown genotypes using a reference panel of fully genotyped individuals.
  • "Our benchmarking results demonstrate that we have the world's leading genotype imputation method," proclaimed Dr. Puya Yazdi, the study's lead.
  • "Additionally, our method is especially more accurate when it comes to imputing rare variants, which are more important clinically speaking.

Fairtility Unveils CHLOE OQ™ Expanding its Offering into Fertility Preservation

Retrieved on: 
Monday, June 26, 2023
CE, Pregnancy, ESHRE, Life, Oocyte, Woman, Fertilisation, Fertility clinic, IVF, Egg donation, TEL, Fertility preservation, Patient, Fertility, Biology, Human Reproduction (journal), Entrepreneurship, European Society of Human Reproduction and Embryology, Reproduction, Myllocerus discolor, Pregnancy rate, Egg, Mineral oil, Medical device

TEL AVIV, Israel, June 26, 2023 /PRNewswire/ -- Fairtility, the transparent AI innovator powering reproductive care for improved outcomes, today announced the launch of CHLOE OQ™, bringing Oocyte Quality Insights to CHLOE's core technology suite of capabilities and expanding the applicability of its AI-driven decision support tool to fertility preservation. The solution will be unveiled at the 39th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) being held in Copenhagen, Denmark from June 25 to 28, 2023.

Key Points: 
  • With CE declared for CHLOE OQ™, the new Oocyte Quality Insights capability offers IVF professionals comprehensive information to support decision making as patients undergo fertility preservation or assisted reproductive journeys.
  • However, assessing oocyte quality has remained a statistical gamble," said Dr. Cristina Hickman, Chief Clinical Officer of Fairtility.
  • Egg Donation: CHLOE OQ helps fertility clinics and egg banks to further assess the quality of donor eggs, ensuring equitable distribution to recipients.
  • CHLOE OQ now provides decision support for fertility preservation, egg donation, and female-factor infertility in IVF treatment.

Instituto Bernabeu creates the first AI International Unit applied to Reproductive Medicine

Retrieved on: 
Wednesday, June 7, 2023
Male, Pregnancy, IB Group 3 subjects, ESHRE, International unit, Woman, Infertility, Prognosis, Medicine, Research, Multimedia, Fertilisation, Reproduction, Patient, Child, Fertility, Artificial intelligence, Human Reproduction (journal), Knowledge, Diagnosis, AI, European Society of Human Reproduction and Embryology, Congress, Reproductive medicine, Gynaecology, Reproductive endocrinology and infertility, Egg, Medical device, Embryology

After a recognized research trajectory in the use of Artificial Intelligence, Instituto Bernabeu has just created the first International Unit specialized in AI applied to Reproductive Medicine.

Key Points: 
  • After a recognized research trajectory in the use of Artificial Intelligence, Instituto Bernabeu has just created the first International Unit specialized in AI applied to Reproductive Medicine.
  • "This world-first unit is the result of our Scientifics successful work in the AI field in recent years.
  • Thanks to AI, these patients' diagnosis and prognosis will significantly improve", points out the IB Group's medical co-director Andrea Bernabeu.
  • Among the members of this new unit, highly skilled and renowned specialists in the different areas stand out: Instituto Bernabeu Mallorca medical director, Dr. Jordi Suñol; Instituto Bernabeu Group Embryology Unit director, Dr. Jorge Ten; Congenital Defects Unit director, the biochemist Dr. José Antonio Ortiz; and Instituto Bernabeu Madrid Embryology director, Leyre Herrero.

Ferring Announces Ground-Breaking and Inclusive Family Building Benefits Package for All Its Employees Globally

Retrieved on: 
Thursday, July 14, 2022
Health, Pharmaceutical, Maternal health, Compliance, Infertility, Family, Multimedia, Awareness, European Society of Human Reproduction and Embryology, Environment, ART, Urology, Embryology, Human Reproduction (journal), Patient, Saint-Prex, Reproduction, Love, Gastroenterology, Research, Miscarriage, Executive Committee, Reproductive medicine, Ferring Pharmaceuticals, Investor, Mental health, European Society of Cardiology, Fertility, World Health Organization, Mother, Adoption, Medication, Parent, Birth control, Health insurance, Ferring

As part of this commitment, Ferring has announced the introduction of a new global family building benefits package for its employees.

Key Points: 
  • As part of this commitment, Ferring has announced the introduction of a new global family building benefits package for its employees.
  • View the full release here: https://www.businesswire.com/news/home/20220707005467/en/
    The comprehensive package recognises the complexities of building a family and aims to enable different family building options by removing the financial barriers and providing access to quality care.
  • Building on the long-standing fertility benefits package offered to its US-based employees via its provider, Progyny, Ferring has now engaged Carrot, to support its employees in the rest of the world.
  • The new family building support package ensures a global standard for support irrespective of location, role or family circumstances.

Long-term Infant Data Provides Reassurance on Novel Capacitation - In vitro Maturation (CAPA-IVM) Fertility Method

Retrieved on: 
Wednesday, July 6, 2022
TD, Patient, RNA transfection, IVM, Infant, GLOBE, Problem solving, Oocyte, IVF, ESHRE, Polycystic ovary syndrome, Communication, European Society of Human Reproduction and Embryology, Human Reproduction (journal), Reproductive medicine, Safety, Physician, Randomized controlled trial, Birth control, Medical device, Embryology, HCMC

The study was designed to detect developmental delay in children in terms of communication, gross motor, fine motor, problem solving and personal-social behavior.

Key Points: 
  • The study was designed to detect developmental delay in children in terms of communication, gross motor, fine motor, problem solving and personal-social behavior.
  • It included a total of 231 children who were evaluated at 6 months, 12 months and 24 months after birth.
  • Dr. Vuong believes that continuing building evidence on CAPA-IVM is important to physicians considering alternative approaches to current fertility treatment.
  • CAPA-IVM is a novel approach to in-vitro maturation of oocytes recovered after no or minimal ovarian stimulation, that incorporates a capacitation step in the maturation of oocytes in vitro which enhances oocyte developmental competence.

Fairtility Granted CE Mark Under New European Medical Device Regulation (MDR) for AI Decision Support Tool, CHLOE EQ™

Retrieved on: 
Tuesday, July 5, 2022
Efficiency, TEL, Patient, LinkedIn, CEO, MDR, MDD, EMR, Classification, IVF, Medical Devices Directive, PN, Compliance, ESHRE, Fertility clinic, TLI, CE, Workflow, CE marking, European Society of Human Reproduction and Embryology, Entrepreneurship, Human Reproduction (journal), AI, Infertility, Medical device, Twitter, Fertilisation, Algorithm, Mineral oil, Embryology, European, EU

TEL AVIV, Israel, July 5, 2022 /PRNewswire/ -- Fairtility™, the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, today announced its AI decision support tool CHLOE EQ™ earned the CE Mark under the European Medical Devices Regulation (MDR) regulatory requirements. CHLOE EQ™ is now commercially available to IVF fertility clinics across Europe.

Key Points: 
  • TEL AVIV, Israel, July 5, 2022 /PRNewswire/ -- Fairtility , the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, today announced its AI decision support tool CHLOE EQ earned the CE Mark under the European Medical Devices Regulation (MDR) regulatory requirements.
  • CHLOE EQ is an AI decision support tool that was developed to provide Embryo Viability Assessment which supports the prediction of blastulation, the prediction of implantation and ploidy and, ranks embryos in order of priority.
  • The European MDR came into effect in May 2021 and serves as the new European legal framework for medical devices.
  • MDR has more stringent requirements for demonstrated compliance, vis a visthe obsolete Medical Device Directive (MDD), the previous industry standard.

TMRW LIFE SCIENCES APPOINTS ELIZABETH CARR, FIRST AMERICAN BORN THROUGH IVF, AS DIRECTOR OF CLINIC AND PRODUCT MARKETING

Retrieved on: 
Wednesday, March 16, 2022
Conception, List of life sciences, Technology, Education, Egg, ASRM, Patient, Reproductive medicine, United Nations, RFID, Virginia Society for Human Life, Automation, Knowledge, Adoption, Fertility clinic, TMRW, ESHRE, Awareness, Parent, IVF, European Society of Human Reproduction and Embryology, Software, First Nations in Ontario, American Society for Reproductive Medicine, Medical device, Embryology

NEW YORK, March 16, 2022 /PRNewswire/ -- TMRW Life Sciences, creator of the first and only automated solution for the safe management of frozen eggs and embryos central to the IVF process, announced today Elizabeth Carr—the first U.S. baby born through IVF—is joining the team.

Key Points: 
  • Elizabeth will spearhead all clinic and product marketing efforts for TMRW as the innovative specimen management technology rolls out across fertility clinics in the U.S., with Europe to quickly follow.
  • TMRW is already in operation in leading fertility clinics across the country, including Vios Fertility Institute/Kindbody, Boston IVF, San Diego Fertility Clinic, Conceptions, and Colorado Center for Reproductive Medicine in Denver.
  • I'm incredibly inspired by both the TMRW team and the TMRW technology in that mission with this state-of-the-art solution replacing outdated and manual systems.
  • By bringing her personal insightsand extensiveexperience to TMRW, Elizabeth will play a significant role as TMRW leads in setting a new standard in fertility care."